PURPOSE: To report the incidence of Pediatric Oncology Group (POG) Grade 3 or 4 ototoxicity in a cohort of patients treated with craniospinal irradiation (CSI) followed by posterior fossa (PF) and/or tumor bed (TB) boost using intensity-modulated radiation therapy (IMRT). METHODS AND MATERIALS: From 1998 to 2006, 44 patients with medulloblastoma were treated with CSI followed by IMRT to the PF and/or TB and cisplatin-based chemotherapy. Patients with standard-risk disease were treated with 18 to 23.4 Gy CSI followed by either a (1) PF boost to 36 Gy and TB boost to 54 to 55.8 Gy or (2) TB boost to 55.8 Gy. Patients with high-risk disease received 36 to 39.6 Gy CSI followed by a (1) PF boost to 54 to 55.8 Gy, (2) PF boost to 45 Gy and TB boost to 55.8 Gy, or (3) TB boost to 55.8 Gy. Median audiogram follow-up was 41 months (range, 11-92.4 months). RESULTS: POG Grade Ototoxicity 0, 1, 2, 3. and 4 was found in 29, 32, 11, 13. and 3 ears. respectively, with POG Grade 3 or 4 accounting for 18.2% of cases. There was a statistically significant difference in mean radiation dose (D(mean)) cochlea according to degree of ototoxicity, with D(mean) cochlea increasing with severity of hearing loss (p = 0.027). CONCLUSIONS: Severe ototoxicity was seen in 18.2% of ears in children treated with IMRT boost and cisplatin-based chemotherapy. Increasing dose to the cochlea was associated with increasing severity of hearing loss.
PURPOSE: To report the incidence of Pediatric Oncology Group (POG) Grade 3 or 4 ototoxicity in a cohort of patients treated with craniospinal irradiation (CSI) followed by posterior fossa (PF) and/or tumor bed (TB) boost using intensity-modulated radiation therapy (IMRT). METHODS AND MATERIALS: From 1998 to 2006, 44 patients with medulloblastoma were treated with CSI followed by IMRT to the PF and/or TB and cisplatin-based chemotherapy. Patients with standard-risk disease were treated with 18 to 23.4 Gy CSI followed by either a (1) PF boost to 36 Gy and TB boost to 54 to 55.8 Gy or (2) TB boost to 55.8 Gy. Patients with high-risk disease received 36 to 39.6 Gy CSI followed by a (1) PF boost to 54 to 55.8 Gy, (2) PF boost to 45 Gy and TB boost to 55.8 Gy, or (3) TB boost to 55.8 Gy. Median audiogram follow-up was 41 months (range, 11-92.4 months). RESULTS: POG Grade Ototoxicity 0, 1, 2, 3. and 4 was found in 29, 32, 11, 13. and 3 ears. respectively, with POG Grade 3 or 4 accounting for 18.2% of cases. There was a statistically significant difference in mean radiation dose (D(mean)) cochlea according to degree of ototoxicity, with D(mean) cochlea increasing with severity of hearing loss (p = 0.027). CONCLUSIONS: Severe ototoxicity was seen in 18.2% of ears in children treated with IMRT boost and cisplatin-based chemotherapy. Increasing dose to the cochlea was associated with increasing severity of hearing loss.
Authors: Eric M Thompson; Alexa Bramall; James E Herndon; Michael D Taylor; Vijay Ramaswamy Journal: J Neurooncol Date: 2018-05-23 Impact factor: 4.130
Authors: M Balducci; S Chiesa; D Chieffo; S Manfrida; N Dinapoli; A Fiorentino; F Miccichè; V Frascino; C Anile; V Valentini; B De Bari Journal: J Neurooncol Date: 2011-07-31 Impact factor: 4.130
Authors: Eric M Thompson; Michael Brown; Elena Dobrikova; Vijay Ramaswamy; Michael D Taylor; Roger McLendon; Jennifer Sanks; Vidya Chandramohan; Darell Bigner; Matthias Gromeier Journal: J Neuropathol Exp Neurol Date: 2018-08-01 Impact factor: 3.685
Authors: J J Yang; J Y S Lim; J Huang; J Bass; J Wu; C Wang; J Fang; E Stewart; E H Harstead; S E; G W Robinson; W E Evans; A Pappo; J Zuo; M V Relling; A Onar-Thomas; A Gajjar; C F Stewart Journal: Clin Pharmacol Ther Date: 2013-06-11 Impact factor: 6.875
Authors: A Silvani; P Gaviani; E Lamperti; A Botturi; F Dimeco; A Franzini; P Ferroli; L Fariselli; I Milanesi; A Erbetta; B Pollo; A Salmaggi Journal: J Neurooncol Date: 2011-08-27 Impact factor: 4.130
Authors: Surya Rednam; Michael E Scheurer; Adekunle Adesina; Ching C Lau; Mehmet Fatih Okcu Journal: Pediatr Blood Cancer Date: 2012-10-12 Impact factor: 3.167
Authors: Andrew M Heitzer; Alexandra M Villagran; Kimberly Raghubar; Austin L Brown; Miranda L Camet; M Douglas Ris; Jenny H Hanning; M Fatih Okcu; Arnold C Paulino; Murali Chintagumpala; Lisa S Kahalley Journal: J Neurooncol Date: 2019-11-28 Impact factor: 4.130
Authors: Sergiu Scobioala; Ross Parfitt; Peter Matulat; Christopher Kittel; Fatemeh Ebrahimi; Heidi Wolters; Antoinette Am Zehnhoff-Dinnesen; Hans Theodor Eich Journal: Strahlenther Onkol Date: 2017-09-08 Impact factor: 3.621